KR101925671B1 - 데페라시록스의 경구 제제 - Google Patents

데페라시록스의 경구 제제 Download PDF

Info

Publication number
KR101925671B1
KR101925671B1 KR1020157027470A KR20157027470A KR101925671B1 KR 101925671 B1 KR101925671 B1 KR 101925671B1 KR 1020157027470 A KR1020157027470 A KR 1020157027470A KR 20157027470 A KR20157027470 A KR 20157027470A KR 101925671 B1 KR101925671 B1 KR 101925671B1
Authority
KR
South Korea
Prior art keywords
tablet
deferasilox
weight
delete delete
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157027470A
Other languages
English (en)
Korean (ko)
Other versions
KR20150126900A (ko
Inventor
인드라지트 고스
지아-아이 장
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101925671(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20150126900A publication Critical patent/KR20150126900A/ko
Application granted granted Critical
Publication of KR101925671B1 publication Critical patent/KR101925671B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157027470A 2013-03-08 2014-03-06 데페라시록스의 경구 제제 Active KR101925671B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361774893P 2013-03-08 2013-03-08
US61/774,893 2013-03-08
US201361824435P 2013-05-17 2013-05-17
US61/824,435 2013-05-17
PCT/IB2014/059494 WO2014136079A1 (en) 2013-03-08 2014-03-06 Oral formulations of deferasirox

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177010591A Division KR20170045391A (ko) 2013-03-08 2014-03-06 데페라시록스의 경구 제제

Publications (2)

Publication Number Publication Date
KR20150126900A KR20150126900A (ko) 2015-11-13
KR101925671B1 true KR101925671B1 (ko) 2019-02-27

Family

ID=50288212

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157027470A Active KR101925671B1 (ko) 2013-03-08 2014-03-06 데페라시록스의 경구 제제
KR1020177010591A Withdrawn KR20170045391A (ko) 2013-03-08 2014-03-06 데페라시록스의 경구 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177010591A Withdrawn KR20170045391A (ko) 2013-03-08 2014-03-06 데페라시록스의 경구 제제

Country Status (42)

Country Link
US (4) US9283209B2 (enExample)
EP (2) EP2964202B2 (enExample)
JP (3) JP6434429B2 (enExample)
KR (2) KR101925671B1 (enExample)
CN (1) CN105025886B (enExample)
AP (1) AP2015008668A0 (enExample)
AU (2) AU2014224198B2 (enExample)
BR (1) BR112015021254A2 (enExample)
CA (1) CA2890465A1 (enExample)
CL (1) CL2015002495A1 (enExample)
CR (1) CR20150467A (enExample)
CU (1) CU24348B1 (enExample)
CY (2) CY1120021T1 (enExample)
DK (2) DK2964202T3 (enExample)
DO (1) DOP2015000220A (enExample)
EA (1) EA031719B1 (enExample)
EC (1) ECSP15042897A (enExample)
ES (2) ES2663135T5 (enExample)
GE (1) GEP20186810B (enExample)
HR (2) HRP20190173T1 (enExample)
HU (2) HUE036921T2 (enExample)
IL (1) IL240797B (enExample)
JO (1) JO3570B1 (enExample)
LT (2) LT3124018T (enExample)
ME (1) ME03297B (enExample)
MX (1) MX361055B (enExample)
MY (1) MY170303A (enExample)
NI (1) NI201500126A (enExample)
NZ (1) NZ711179A (enExample)
PE (1) PE20151600A1 (enExample)
PH (1) PH12015501981A1 (enExample)
PL (2) PL2964202T3 (enExample)
PT (2) PT2964202T (enExample)
RS (2) RS58317B1 (enExample)
SA (1) SA515360425B1 (enExample)
SG (2) SG11201506491RA (enExample)
SI (2) SI2964202T1 (enExample)
TN (1) TN2015000393A1 (enExample)
TW (2) TWI625136B (enExample)
UY (1) UY35367A (enExample)
WO (1) WO2014136079A1 (enExample)
ZA (1) ZA201506060B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036921T2 (hu) 2013-03-08 2018-08-28 Novartis Ag Orális deferasirox készítmények
US9866684B2 (en) * 2015-02-16 2018-01-09 Microsoft Technology Licensing, Llc Process for real-time data exchange between users on a phone call
WO2016167729A1 (en) * 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
JP2018517734A (ja) * 2015-06-17 2018-07-05 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー デフェラシロクスの改善された製剤およびその作製方法
WO2017158559A1 (en) 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CA3029543C (en) * 2016-07-05 2021-11-23 Jubilant Generics Limited Immediate release pharmaceutical composition of iron chelating agents
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
TR201707764A2 (tr) * 2017-05-29 2018-12-21 Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasiroksun bölünebilir tablet formları.
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
EP3854385A1 (en) * 2020-01-27 2021-07-28 ROS Therapeutics ApS Methotrexate dosage form
WO2022186809A1 (en) * 2021-03-05 2022-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet comprising deferasirox
AU2022289906A1 (en) * 2021-06-07 2023-11-09 R.P. Scherer Technologies, Llc Protective coating for moisture sensitive pharmaceutical compositions
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
WO2025242589A1 (en) 2024-05-21 2025-11-27 Chiesi Farmaceutici S.P.A. Pharmaceutical dosage forms for deferiprone and deferasirox combined therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
KR20070022243A (ko) * 2004-04-08 2007-02-26 노파르티스 아게 데페라시록스 분산성 정제
NZ567155A (en) * 2005-10-19 2010-06-25 Novartis Ag Dispersible tablets comprising deferasirox
EP2062572A1 (en) † 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
WO2009106824A2 (en) 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
EP2291360A2 (en) * 2008-04-21 2011-03-09 Actavis Group PTC ehf. Solid state forms of deferasirox salts and process for the preparation thereof
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox
WO2010143006A1 (en) * 2009-06-10 2010-12-16 Carlo Ghisalberti Orally bioavailable iron chelators in the treatment of an inflammatory bowel disease
CA2805568A1 (en) * 2010-07-08 2012-01-12 Ratiopharm Gmbh Oral dosage form of deferasirox
PE20140166A1 (es) 2010-10-01 2014-02-17 Cipla Ltd Composicion farmaceutica que comprende deferasirox
HUE036921T2 (hu) 2013-03-08 2018-08-28 Novartis Ag Orális deferasirox készítmények
WO2017158559A1 (en) 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제

Also Published As

Publication number Publication date
ES2663135T3 (es) 2018-04-11
EA031719B1 (ru) 2019-02-28
PT2964202T (pt) 2019-02-06
CN105025886B (zh) 2019-01-15
PH12015501981B1 (en) 2016-01-11
JP2016510068A (ja) 2016-04-04
ES2663135T5 (en) 2024-12-16
PL3124018T3 (pl) 2018-05-30
IL240797A0 (en) 2015-10-29
AU2017203897A1 (en) 2017-06-29
RS56890B1 (sr) 2018-04-30
SI3124018T1 (en) 2018-04-30
JO3570B1 (ar) 2020-07-05
EP3124018B1 (en) 2017-12-20
KR20170045391A (ko) 2017-04-26
DOP2015000220A (es) 2015-11-30
SA515360425B1 (ar) 2018-01-21
LT2964202T (lt) 2019-02-11
ES2708955T3 (es) 2019-04-12
CL2015002495A1 (es) 2016-03-04
EP2964202A1 (en) 2016-01-13
HRP20180387T1 (hr) 2018-04-20
CA2890465A1 (en) 2014-09-12
AU2014224198B2 (en) 2017-06-15
TN2015000393A1 (en) 2017-01-03
ME03297B (me) 2019-07-20
MX361055B (es) 2018-11-26
EA201591665A1 (ru) 2015-12-30
JP2018162255A (ja) 2018-10-18
HRP20190173T1 (hr) 2019-03-22
HUE036921T2 (hu) 2018-08-28
TW201838623A (zh) 2018-11-01
IL240797B (en) 2022-01-01
US20160220493A1 (en) 2016-08-04
HK1212242A1 (en) 2016-06-10
PT3124018T (pt) 2018-03-22
US20180221285A1 (en) 2018-08-09
AP2015008668A0 (en) 2015-08-31
BR112015021254A2 (pt) 2017-07-18
NI201500126A (es) 2015-11-18
TWI625136B (zh) 2018-06-01
MX2015011962A (es) 2016-07-07
TW201442742A (zh) 2014-11-16
GEP20186810B (en) 2018-01-25
PL2964202T3 (pl) 2019-04-30
NZ711179A (en) 2018-07-27
SI2964202T1 (sl) 2019-02-28
MY170303A (en) 2019-07-17
CU20150110A7 (es) 2016-04-25
US20170290811A1 (en) 2017-10-12
ZA201506060B (en) 2016-12-21
KR20150126900A (ko) 2015-11-13
EP2964202B1 (en) 2018-10-31
ES2708955T5 (es) 2023-11-10
US9283209B2 (en) 2016-03-15
EP3124018A1 (en) 2017-02-01
EP2964202B2 (en) 2023-05-31
EP3124018B2 (en) 2024-04-24
SG10201807204YA (en) 2018-09-27
RS58317B1 (sr) 2019-03-29
DK3124018T3 (en) 2018-03-26
JP6434429B2 (ja) 2018-12-05
JP6739470B2 (ja) 2020-08-12
LT3124018T (lt) 2018-03-12
SG11201506491RA (en) 2015-09-29
CR20150467A (es) 2015-10-27
DK2964202T3 (en) 2019-02-25
WO2014136079A1 (en) 2014-09-12
PH12015501981A1 (en) 2016-01-11
UY35367A (es) 2014-10-31
ECSP15042897A (es) 2019-03-29
CN105025886A (zh) 2015-11-04
PE20151600A1 (es) 2015-11-26
CY1120021T1 (el) 2018-12-12
US20150017241A1 (en) 2015-01-15
AU2017203897B2 (en) 2019-02-14
TWI686215B (zh) 2020-03-01
CU24348B1 (es) 2018-05-08
HUE041224T2 (hu) 2019-05-28
CY1121315T1 (el) 2020-05-29
JP2020180123A (ja) 2020-11-05
AU2014224198A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
JP6739470B2 (ja) デフェラシロクスの経口製剤
CN102946869B (zh) γ-羟基丁酸的速释制剂及剂型
CZ304416B6 (cs) Farmaceutická kompozice obsahující entacapon, levodopu a karbidopu a léčivo pro léčení Parkinsonovy choroby
EA037375B1 (ru) Составы с замедленным высвобождением, содержащие колхицин, и способы их применения
JP6697539B2 (ja) コルヒチンの徐放性製剤およびその使用方法
US20180071220A1 (en) Oral formulations of deferasirox
US20220000787A1 (en) Delayed release pharmaceutical composition of prednisone and preparation thereof
HK1212242B (en) Oral formulations of deferasirox
HK1229224B (en) Oral formulations of deferasirox
HK1229224A1 (en) Oral formulations of deferasirox
HK1229224A (en) Oral formulations of deferasirox

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A107 Divisional application of patent
A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8